Ozempic and Anxiety: Side Effects and Interactions (2026)

Anxiety is one of the more nuanced topics that comes up in conversations about GLP-1 medications. Some people report that starting Ozempic worsened their anxiety, at least initially. Others describe a reduction in anxiety alongside weight loss and improved metabolic health. And a smaller group notices no change at all. The picture isn’t straightforward, which is exactly why it deserves a careful look rather than a simple reassurance or a blanket warning. Here’s what the current evidence shows about semaglutide and anxiety, what’s likely driving the different experiences, and what people with anxiety disorders should know before starting treatment.

What the Clinical Trial Data Shows

Anxiety-related adverse events are not prominently flagged in the major semaglutide trials, which is reassuring at a population level. The STEP trials, which enrolled thousands of participants over 68 weeks, did not identify anxiety as a significant safety signal. Rates of anxiety-related adverse events were broadly similar between semaglutide and placebo groups.

That said, clinical trial populations tend to exclude people with significant psychiatric histories, which limits how well this data reflects real-world experiences. Post-market surveillance and patient-reported outcomes have painted a more nuanced picture, with a meaningful subset of people describing anxiety changes, particularly in the early weeks of treatment.

The FDA added a note about suicidal ideation and depression to GLP-1 medication labels in 2023 following reports, though subsequent analysis has not confirmed a causal relationship. The European Medicines Agency conducted a similar review and found no established link. The current consensus is that GLP-1 medications do not appear to cause anxiety or depression at the population level, but individual responses vary and monitoring matters.

Why Some People Experience Anxiety on Ozempic

Several mechanisms can explain anxiety symptoms that emerge after starting GLP-1 treatment, most of which are indirect rather than a direct neurological effect of semaglutide.

Blood sugar fluctuations are the most common culprit. As semaglutide improves insulin sensitivity and reduces glucose absorption, some people experience mild hypoglycemic episodes, particularly if they’re eating significantly less than usual. Low blood sugar produces symptoms that closely mimic anxiety: heart racing, shakiness, sweating, lightheadedness, and a sense of impending doom. People who don’t recognize these as glucose-related can interpret them as anxiety attacks.

Nausea and gastrointestinal discomfort, common in the early weeks of GLP-1 treatment, also activate the body’s stress response. Persistent nausea is physiologically stressful and can heighten anxiety in people who are already prone to it. For people with health anxiety specifically, new and unfamiliar physical sensations from a medication can become a significant focus of worry.

The disruption of eating patterns is another factor. Food serves many psychological functions beyond nutrition, including stress relief, comfort, and emotional regulation. When GLP-1 medications significantly reduce appetite and change the relationship with food, people who relied on eating as a coping mechanism may find that the anxiety those eating patterns were managing becomes more present. This is particularly relevant for people with a history of emotional eating or binge eating disorder, as covered in the GLP-1 for binge eating disorder article.

Why Some People Experience Reduced Anxiety on Ozempic

The other side of the picture is equally real. A significant number of people on GLP-1 medications report improvements in anxiety alongside weight loss, and several mechanisms explain this.

Weight loss itself reduces anxiety. Excess weight is associated with elevated cortisol, systemic inflammation, and disrupted sleep, all of which fuel anxiety. As these factors improve with weight loss, anxiety often follows. The improvement in body image and physical confidence that accompanies meaningful weight loss also has measurable psychological benefits.

GLP-1 receptors are present in brain regions involved in stress and anxiety regulation, including the amygdala and hippocampus. Animal studies have shown that GLP-1 receptor activation in these areas reduces stress-induced anxiety behaviors. Whether this translates meaningfully to humans is still being studied, but it provides a plausible neurological basis for the anxiety reductions some people report.

Improved sleep quality, which often accompanies weight loss and sleep apnea improvement in people on GLP-1 medications, is one of the most powerful natural anxiolytics available. Many people who see sleep improvements on semaglutide notice corresponding reductions in baseline anxiety.

Anxiety Medications and GLP-1: Interactions to Know

For people already taking medications for anxiety, a few practical considerations are worth discussing with a prescriber before starting GLP-1 treatment.

SSRIs and SNRIs, the most commonly prescribed medications for anxiety, do not have significant pharmacokinetic interactions with semaglutide. The gastric emptying slowdown affects oral medication absorption generally, but SSRIs and SNRIs are not particularly sensitive to this effect at therapeutic doses.

Benzodiazepines, used for acute anxiety management, are similarly not expected to interact significantly with semaglutide at a pharmacokinetic level. That said, benzodiazepines affect appetite and metabolism in ways that can complicate the clinical picture when starting GLP-1 treatment.

Buspirone, used for generalized anxiety disorder, is worth discussing with a prescriber specifically because it is more absorption-sensitive than SSRIs. If you take buspirone and are starting semaglutide, consistent timing of your buspirone dose relative to meals becomes more important.

Consider this scenario: a 38-year-old woman with generalized anxiety disorder managed on an SSRI starts compounded semaglutide. In the first three weeks she notices increased heart racing and a heightened sense of unease. Her prescriber identifies mild hypoglycemic episodes as the likely cause and recommends she eat a small protein-containing snack before her doses. Symptoms resolve by week five. By month four, having lost 18 pounds, she reports her baseline anxiety is lower than it has been in years.

Managing Anxiety Symptoms During Dose Escalation

The early weeks of GLP-1 treatment, when gastric emptying changes are most pronounced and the body is adjusting to significantly reduced intake, are the period of highest risk for anxiety-adjacent symptoms. A few practical strategies reduce this risk.

Eat consistently even when appetite is suppressed. The appetite reduction GLP-1 medications produce can be dramatic enough that some people go hours without eating, which destabilizes blood sugar and increases anxiety vulnerability. Small, protein-rich meals at regular intervals help maintain glucose stability.

Stay well hydrated. Dehydration, which can occur if nausea reduces fluid intake, amplifies anxiety symptoms and causes heart palpitations that can be alarming.

Slow the dose escalation if needed. GLP-1 medications are typically escalated on a four-week schedule, but there is no clinical rule requiring strict adherence to this timeline. Staying at a lower dose for an additional month is a reasonable approach for people who experience significant side effects, including anxiety, during escalation.

When to Flag Anxiety Changes With Your Provider

If you’re on GLP-1 treatment and experiencing new or worsening anxiety, it’s worth flagging with your prescriber sooner rather than later. In most cases, the cause is identifiable and addressable. In a small number of cases, the medication may genuinely not be well-tolerated from a psychological standpoint, and alternatives exist.

For people with significant pre-existing anxiety disorders, involving a mental health provider alongside the GLP-1 prescriber from the start of treatment makes the process smoother and ensures any changes in mental health status are properly contextualized.

The depression and GLP-1 medications article covers the broader mental health picture of GLP-1 treatment, including the overlapping evidence on mood, anxiety, and psychological wellbeing that is relevant for anyone with a mental health history starting these medications.

Getting Started

TrimRx providers review your full health history during intake, including any mental health conditions and current psychiatric medications. This allows for personalized guidance on what to watch for and how to manage the early adjustment period. The compounded semaglutide program offers an accessible and affordable entry point for people exploring GLP-1 treatment.

To find out whether you’re a candidate, take the intake assessment and a licensed provider will review your situation.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.